Research Reports | Market Assessment
August 2014

Rheumatoid Arthritis [Tofacitinib (Xeljanz) (Wave 5)] | LaunchTrends | US | 2014

This report is a series of four post-launch reports that evaluates the trial and usage of XELJANZ (tofacitinib) among rheumatologists for the treatment of rheumatoid arthritis (RA).
LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products at one month, three months, six months and one year post launch. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and change market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports